Samsrita Labs
DRHABEEBULLAHLIFELTD NSE
Samsrita Labs
Healthcare ServicesNSE: DRHABEEBULLAHLIFELTD BSE: 539267 Healthcare Service Provider
Key Fundamentals
MicrocapHealthcare Service ProviderHealthcare ServicesMarket Cap
₹26.81 Cr
Volatility
Moderate
P/E Ratio
-3.5
EBITDA
₹-8.70 Cr
Return on Equity
-73.9%
Debt to Equity
0.14
Book Value
₹5.17
EPS
₹0
52W High
₹25.27
52W Low
₹10.15
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
1- Company has reduced debt.
Weaknesses
5- Company has low interest coverage ratio.
- Promoter holding is low: 25.4%
- Company has a low return on equity of -23.9% over last 3 years.
- Company has high debtors of 365 days.
- Promoter holding has decreased over last 3 years: -27.4%
Growth Rate
Revenue Growth
0% level than
3Y
Net Income Growth
60%
Cash Flow Change
—
ROE
-62.5% lower than
3Y
ROCE
158%
EBITDA Margin (Avg.)
-200%
Quarterly Results
| Particulars | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2024 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.42 | 0.24 | 0.01 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.02 | 0 |
| Expenses | 0.89 | 0.76 | 0.32 | 0.35 | 0.23 | 0.07 | 0.08 | 0.06 | 0 | 4.93 | 3.36 | 0.17 | 0.31 |
| Operating Profit | -0.47 | -0.52 | -0.31 | -0.35 | -0.23 | -0.07 | -0.08 | -0.06 | 0 | -4.93 | -3.36 | -0.15 | -0.31 |
| OPM % | -111.9% | -216.67% | -3100% | — | — | — | — | — | — | — | — | -750% | — |
| Other Income | 0.05 | 0.05 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0 | 0 | 0 | 0.03 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0.01 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| PBT | -0.42 | -0.48 | -0.27 | -0.31 | -0.19 | -0.03 | -0.04 | -0.02 | 0 | -4.93 | -3.36 | -0.12 | -0.31 |
| Tax % | 0% | -14.58% | 0% | -3.23% | 0% | -66.67% | 0% | 0% | — | 0% | 0% | 0% | 0% |
| Net Profit | -0.42 | -0.41 | -0.27 | -0.3 | -0.19 | -0.01 | -0.04 | -0.02 | 0 | -4.55 | -2.94 | -0.48 | -0.19 |
| EPS in Rs | -0.28 | -0.28 | -0.18 | -0.2 | -0.13 | -0.01 | -0.03 | -0.01 | 0 | -2 | -1.29 | -0.21 | -0.08 |
Profit & Loss
| Particulars | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1.28 | 0.58 | 1.9 | 1.43 | 0.01 | 0.02 | 0.02 | 0 | 0 | 0.02 | 0.02 |
| Expenses | 1.86 | 1.71 | 4.34 | 3.62 | 0.92 | 0.43 | 1.01 | 0.25 | 0.26 | 8.73 | 8.77 |
| Operating Profit | -0.58 | -1.13 | -2.44 | -2.19 | -0.91 | -0.41 | -0.99 | -0.25 | -0.26 | -8.71 | -8.75 |
| OPM % | -45.31% | -194.83% | -128.42% | -153.15% | -9100% | -2050% | -4950% | — | — | -43550% | -43750% |
| Other Income | 0.01 | 0.03 | 0.11 | 0.16 | 0.15 | 1.91 | 0.29 | 0 | 0 | 0.03 | 0.03 |
| Interest | 0 | 0 | 0.01 | 0.01 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0.01 | 0.01 | 0.02 | 0.02 | 0.01 | 0.01 | 0 | 0 | 0 | 0 | 0 |
| PBT | -0.58 | -1.11 | -2.36 | -2.06 | -0.77 | 1.49 | -0.7 | -0.25 | -0.26 | -8.68 | -8.72 |
| Tax % | 124.14% | -5.41% | -1.27% | -3.4% | 0% | 0% | 0% | 0% | 0% | 0% | — |
| Net Profit | -1.31 | -1.05 | -2.33 | -1.98 | -0.77 | 1.49 | -0.71 | -0.26 | -0.28 | -8.16 | -8.16 |
| EPS in Rs | -1.28 | -0.89 | -1.69 | -1.34 | -0.52 | 1.01 | -0.48 | -0.18 | -0.19 | -3.59 | -3.58 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | — |
Balance Sheet
| Particulars | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 10.26 | 11.76 | 13.81 | 14.81 | 14.81 | 14.81 | 14.81 | 14.81 | 14.81 | 22.75 |
| Reserves | -2.39 | -0.4 | -1.61 | -3.03 | -3.66 | -1.58 | -2.29 | -2.55 | -2.84 | -11 |
| Borrowings | 6.5 | 6.81 | 7.92 | 8.58 | 2.34 | 2.74 | 2.08 | 2.2 | 2.43 | 1.66 |
| Other Liabilities | 4.88 | 4.73 | 6.11 | 7.85 | 3.09 | 1.16 | 0.96 | 1.09 | 1.17 | 0.98 |
| Total Liabilities | 19.25 | 22.9 | 26.23 | 28.21 | 16.58 | 17.13 | 15.56 | 15.55 | 15.57 | 14.39 |
| Fixed Assets | 0.46 | 0.36 | 0.26 | 0.13 | 0.02 | 0.01 | 0.01 | 0.01 | 0 | 0 |
| CWIP | 14.85 | 16.13 | 17.77 | 18.99 | 3.26 | 3.26 | 3.26 | 3.26 | 3.26 | 2 |
| Investments | 0.01 | 0.01 | 0.01 | 0.01 | 4.22 | 4.8 | 4.8 | 4.79 | 4.76 | 9.84 |
| Other Assets | 3.93 | 6.4 | 8.19 | 9.08 | 9.08 | 9.06 | 7.49 | 7.49 | 7.55 | 2.55 |
| Total Assets | 19.25 | 22.9 | 26.23 | 28.21 | 16.58 | 17.13 | 15.56 | 15.55 | 15.57 | 14.39 |
Cash Flow
| Particulars | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating | -0.26 | -3.32 | -2.96 | -1.05 | -0.34 | -0.4 | 0.66 | -0.13 | -0.23 | -4.26 |
| Investing | -1.09 | -1.19 | -1.55 | -1.11 | -0.23 | 0 | 0 | 0 | 0 | 3.26 |
| Financing | 1.27 | 4.83 | 4.19 | 2.17 | 0.55 | 0.4 | -0.67 | 0.13 | 0.22 | 2.63 |
| Net Cash Flow | -0.08 | 0.32 | -0.32 | 0.01 | -0.02 | 0.01 | 0 | 0 | 0 | 1.63 |
| Free Cash Flow | -0.26 | -4.51 | -4.51 | -2.16 | -0.57 | -0.4 | 0.66 | -0.13 | -0.23 | -1 |
| CFO/OP | 45 | 294 | 121 | 48 | 37 | 98 | -67 | 52 | 88 | 49 |
Ratios
| Particulars | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 932 | 1,806 | 425 | 556 | 78,110 | 38,690 | 38,325 | — | — | 365 |
| Inventory Days | 0 | — | — | — | — | 0 | 0 | — | — | 0 |
| Cash Conversion Cycle | 932 | 1,806 | 425 | 556 | 78,110 | 38,690 | 38,325 | — | — | 365 |
| Working Capital Days | -1,115 | -2,259 | -788 | -1,463 | 60,590 | 58,765 | 46,173 | — | — | -29,748 |
| ROCE % | — | -5.44% | -10.11% | -8.45% | -4.07% | 10.12% | -4.58% | -1.72% | -1.8% | -62.42% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Samsrita Labs insights
59 extracted metrics + investor summaries across FY09–FY26.
Documents
1
Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2
24 Apr - Samsrita Labs files FY2025-26 annual disclosure, confirms it is not a Large Corporate. 24 Apr - Samsrita Labs files FY2025-26 annual disclosure, confirms it is not a Large Corporate.
2
Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2
14h - Samsrita Labs files FY2025-26 annual disclosure, confirms it is not a Large Corporate. 14h - Samsrita Labs files FY2025-26 annual disclosure, confirms it is not a Large Corporate.
3
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
23 Apr - Samsrita Labs confirms it is not a Large Corporate; outstanding borrowings were nil as of 31 March 2026. 23 Apr - Samsrita Labs confirms it is not a Large Corporate; outstanding borrowings were nil as of 31 March 2026.
4
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
10h - Samsrita Labs confirms it is not a Large Corporate; outstanding borrowings were nil as of 31 March 2026. 10h - Samsrita Labs confirms it is not a Large Corporate; outstanding borrowings were nil as of 31 March 2026.
5
Clarification On Price Movement
18 Apr - 18 Apr 2026: Samsrita Labs clarified stock movement was market-driven and no information was withheld. 18 Apr - 18 Apr 2026: Samsrita Labs clarified stock movement was market-driven and no information was withheld.
Frequently Asked Questions about Samsrita Labs
What does Samsrita Labs Ltd do?
Incorporated in 1996, Samsarita Labs Ltd is
in the business of healthcare services including hospital, diagnostics, Pharma, and Biotechnology (R&D)
Where is Samsrita Labs Ltd (539267) listed?
Samsrita Labs Ltd trades as DRHABEEBULLAHLIFELTD on the NSE and under code 539267 on the BSE.
Which sector does Samsrita Labs Ltd belong to?
Samsrita Labs Ltd is classified under the Healthcare Services sector, in the Healthcare Service Provider industry.
What is the market capitalisation of Samsrita Labs Ltd?
Samsrita Labs Ltd has a market capitalisation of ₹26.81 Cr, which places it in the Small Cap band.
What is the PE ratio of Samsrita Labs Ltd?
Samsrita Labs Ltd trades at a PE ratio of -3.50, on earnings per share of ₹0, against a book value of ₹5.17 per share.
What is the 52-week high and low of Samsrita Labs Ltd?
Over the last 52 weeks Samsrita Labs Ltd has traded between ₹10.15 and ₹25.27.
What is the Return on Equity (ROE) of Samsrita Labs Ltd?
Samsrita Labs Ltd reported a return on equity of -73.90%. Its debt-to-equity ratio is 0.14.
Company Information
Incorporated in 1996, Samsarita Labs Ltd is in the business of healthcare services including hospital, diagnostics, Pharma, and Biotechnology (R&D)
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/539267.md for Samsrita Labs Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.